In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Malcolm Spicer

Malcolm Spicer, Managing Editor – US

Washington, DC
Malcolm Spicer is lead analyst for Pharma intelligence | informa's coverage of the consumer health care products industries. He provides comprehensive and insightful reporting on manufacturing, marketing, regulation, legislation, financial and research news about the nonprescription drug and nutritional product industries. He has worked in this post for 10 years and previously reported for other publications on regulation of the health care industry, on the telecommunications and internet technologies and on the US energy market.

Latest From Malcolm Spicer

CBD Firm Targeting Veterans, Military Takes Broadside On COVID Claims From US Agencies

FTDA and FTC warn Patriot Supreme about noncompliant claims on its website and social media pages promoting CBD to prevent or treat infections from the coronavirus. However, a release Patriot Supreme distributed in July promoting CBD as a COVID-19 remedy remains in online circulation.

Coronavirus COVID-19 Dietary Supplements

US Firms’ Reducing Allergy Claims For Infant Nutritionals Scratch FDA's Enforcement Discretion

“To the extent these claims pertain to the ingestion of peanuts, they are not consistent with the claim in the [2017] Letter of Enforcement Discretion FDA issued in response to a petition for a qualified health claim for ground peanuts and reduced risk of developing peanut allergy,” state CFSAN officials.

Dietary Supplements FDA

Bloodroot, Zinc Make A Corrosive Mix In Homeopathic Topicals, US FDA Warns

Warnings state each’s firm products “are concerning from a public health perspective because they are labeled to contain the ingredients bloodroot (Sanguinaria canadensis) and zinc chloride … known corrosive agents.” The combination results in a corrosive topical agent capable of indiscriminately damaging healthy and diseased tissue alike.

FDA OTC Drugs

US Consumers 'May Already' See CBD As ‘Effective Therapeutic For Health Conditions’ – Study

Results of a JAMA study on why consumers say they use CBD supplements and an accompanying commentary emphasize that FDA should eliminate "unsupported claims of medical benefit” for CBDs and other cannabinoids.

Cannabidiol CBD OTC Drugs

NSAIDs Marketed In US Will Have Stronger Label Warning About Risks During Late Pregnancy

In Drug Safety Communication, FDA says it is requiring labeling changes for Rx as well as OTC NSAIDs due to risk of rare but serious kidney problems in an unborn baby.

Ingredients OTC Drugs

US FDA Keeps Estimate For NDI Notification Burden At Level Supplement Industry Doubts

FDA again sets expected costs at level supplement industry repeatedly has said drastically underestimates spending on preparing and submitting NDI notifications. But FDA says developing scientific evidence to support a notification is separate from submitting the information to the agency.

FDA Dietary Supplements
See All
UsernamePublicRestriction

Register